• Home
  • Search Results
  • Pharmacological STING Activation Is a Potential Alternative to Overcome Drug-Resistance in Melanoma.

Pharmacological STING Activation Is a Potential Alternative to Overcome Drug-Resistance in Melanoma.

Frontiers in oncology (2020-06-02)
Sandhya Chipurupalli, Raja Ganesan, S P Dhanabal, M Suresh Kumar, Nirmal Robinson
ABSTRACT

Melanoma is the most aggressive type of skin cancer and resistance to the conventional chemotherapy is the major cause for its poor prognosis. Metabolic perturbations leading to increased production of reactive oxygen species activate NRF2-dependent anti-oxidative responses to survive oxidative stress. This protective function of NRF2 is the primary cause for therapy resistance in cancer as anti-cancer agents such as BRAF inhibitors also induce NRF2-dependent antioxidative response. We had reported that type I interferons produced upon activation of STING, abrogates NRF2 function. Therefore, we investigated if STING agonists such as the newly developed dimeric aminobenzimidazole (diABZI) could sensitize melanoma cells to the clinically used BRAF inhibitors. Our results reveal that pharmacological activation of STING by diABZI, down regulates NRF2-dependent anti-oxidative responses and potentiates cell-death in melanoma cells when used in combination with BRAF inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
CDDO Methyl Ester, ≥98% (HPLC)